Humana (HUM) Upgraded by Credit Suisse Group to Outperform

Humana (NYSE:HUM) was upgraded by equities research analysts at Credit Suisse Group from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Thursday, Marketbeat reports. The firm presently has a $246.00 price target on the insurance provider’s stock, down from their previous price target of $264.90. Credit Suisse Group’s target price suggests a potential downside of 7.28% from the stock’s current price.

HUM has been the subject of several other reports. BMO Capital Markets raised their target price on Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. Royal Bank of Canada reissued a “sector perform” rating and issued a $242.00 price objective (down previously from $245.00) on shares of Humana in a report on Thursday, November 9th. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 19th. Jefferies Group reissued a “hold” rating and issued a $257.00 price objective on shares of Humana in a report on Friday, October 13th. Finally, Morgan Stanley decreased their price objective on Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a report on Thursday, November 9th. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Humana currently has an average rating of “Buy” and an average price target of $269.68.

Shares of Humana (NYSE:HUM) traded up $2.95 during trading on Thursday, hitting $265.32. The stock had a trading volume of 1,640,000 shares, compared to its average volume of 1,218,790. Humana has a 1 year low of $203.36 and a 1 year high of $293.35. The stock has a market cap of $37,903.62, a price-to-earnings ratio of 15.91, a PEG ratio of 1.54 and a beta of 0.93. The company has a current ratio of 1.85, a quick ratio of 1.61 and a debt-to-equity ratio of 0.48.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm had revenue of $13.19 billion during the quarter, compared to analyst estimates of $13.14 billion. During the same period last year, the firm posted $2.34 EPS. The business’s revenue was up 2.4% compared to the same quarter last year. equities analysts forecast that Humana will post 13.85 EPS for the current fiscal year.

Humana declared that its Board of Directors has approved a stock repurchase program on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

In other Humana news, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total value of $340,027.28. Following the completion of the transaction, the vice president now owns 11,557 shares in the company, valued at approximately $2,843,484.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the completion of the transaction, the senior vice president now owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,115 shares of company stock valued at $2,501,627. 0.80% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. WFG Advisors LP boosted its stake in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares during the period. Fieldpoint Private Securities LLC bought a new position in Humana in the 3rd quarter worth about $115,000. ClariVest Asset Management LLC bought a new position in Humana in the 3rd quarter worth about $144,000. Daiwa SB Investments Ltd. boosted its stake in Humana by 44.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after purchasing an additional 220 shares during the period. Finally, Virtu Financial LLC bought a new position in Humana in the 4th quarter worth about $204,000. Institutional investors and hedge funds own 94.39% of the company’s stock.

WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/11/humana-hum-upgraded-by-credit-suisse-group-to-outperform.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply